Next, we employed a cellular model based on a triple-negative breast cancer cell line, MDA-MB-468, engineered to express either low or high levels of HER2 along with constitutive high levels of PD-L1 (Supplementary Fig. 9a). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.